Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
The Catholic University of Korea
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06367998CT.gov Effect of Pregabalin on Shoulder Pain in Patients With Central Sensitization After Arthroscopic Rotator Cuff Repair | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Rotator Cuff Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pregabalin (this asset) | The Catholic University of Korea | Approved | BB · 64 |
| Dexasone | Ankara City Hospital Bilkent | P2 | CCC |
| Autologous Conditioned Plasma | Kessler Foundation | P1 | CC |
| Human Autologous Adipose Tissue | Kessler Foundation | Early P1 | C |
| Hyaluronate | Chang Gung Memorial Hospital | N/A | D |
| Marcaine | Federal University of São Paulo | N/A | D |
| Lidocaine | Ankara City Hospital Bilkent | N/A | D |
| Dextrose | Rizki Darmawan | N/A | D |
Other indications for Pregabalin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Focal Epilepsy | — | P4 | A · 82 |
| Peripheral Neuropathy | — | P4 | A · 82 |
| Postherpetic Neuralgia | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pregabalin in Rotator Cuff Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pregabalin-rotator-cuff-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →